The isothiocyanate isolated from Moringa oleifera shows potent anti-inflammatory activity in the treatment of murine sub-acute Parkinson's disease.
Rejuvenation Res. 2016 Jun 1. Epub 2016 Jun 1. PMID: 27245199
The present study was aimed at estimating a possible neuroprotective effect of glucomoringin (4-(-L-rhamnopyranosyloxy)benzyl glucosinolate;) bioactivated with the enzyme myrosinase to form the corresponding isothiocyanate (4-(-L-rhamnopyranosyloxy)benzyl C; moringin) in the treatment or prevention of Parkinson's disease. Here, the beneficial effects of moringin were compared to those ofpure glucomoringin, not enzymatically activated, in in vivo experimental mouse model of sub-acute Parkinson disease. Sub-acute Parkinson disease was induced in C57BL/6 mice by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Mice were daily pretreated for 1 week with moringin (10mg/kg + 5μl myrosinase/mouse) and with glucomoringin (10mg/kg). Behavioural evaluations were also performed in order to assess motor deficits and bradykinesia in MPTP-mice. - Besides, assuming that pre-treatment with moringin could modulate the triggering of inflammatory cascade and the responseto it correlated, we tested its in vitro anti-inflammatory activity by using a model of RAW 264.7 macrophages stimulated with lipopolysaccharide. Achieved results in vivo showed a higher efficacy of moringin compared to glucomoringin not only to modulate inflammatory pathway, but also oxidative stress and apoptotic pathways. In addition, the greater effectiveness of moringin in countering mainly the inflammatory pathway has been corroborated by the results obtained in vitro. The relevance and innovation of the present study lie in the possible use of a safe formulation of a bioactive compound,resulting from exogenous myrosinase-hydrolysis of the natural phytochemical glucomoringin, that can be used in clinical practice as a useful drug for the treatment or prevention of Parkinson's disease.